IceCure's ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024
- None.
- None.
The study's findings indicating the disappearance of hemorrhagic signal and development of necrotic changes post-treatment with IceCure Medical's ProSense® cryoablation technology offer promising implications for the treatment of endometriosis. Cryoablation, a procedure that destroys tissue through freezing, presents a non-surgical alternative that could reduce hospital stays, recovery times and overall healthcare costs. This could potentially lead to increased adoption of the technology, expanding the market for IceCure Medical.
From an investment perspective, the reduction of pain from a median of 7 to 1 is a significant improvement in patient outcomes, which may enhance the company's reputation and drive demand for its ProSense® system. It is essential to monitor subsequent studies for consistency in results and to gauge the long-term efficacy and safety of the treatment, as these factors will influence the technology's market penetration and, consequently, the company's financial performance.
IceCure Medical's presentation at the European Congress of Radiology impacts the company's visibility within the healthcare sector. The technology's minimally invasive approach aligns with the current trend towards less invasive medical procedures. As healthcare providers increasingly prioritize patient comfort and cost-effectiveness, technologies like cryoablation could see a rise in demand.
However, the small sample size of the study (7 women) and its single-site nature call for caution when extrapolating the results to a broader population. The healthcare industry will look for larger, multi-centered studies to validate these findings. Should further research support these initial results, IceCure's stock could experience positive movement as the company captures a larger share of the endometriosis treatment market.
The announcement of the study results at a prestigious conference like ECR could have immediate effects on investor sentiment, potentially leading to short-term stock price volatility for IceCure Medical Ltd. The long-term financial implications, however, hinge on the technology's adoption rate, regulatory approvals and the ability to secure insurance reimbursements for patients.
Investors should also consider the competitive landscape, as other companies may offer alternative treatments for endometriosis. The financial impact on IceCure will depend on how the ProSense® system differentiates itself in terms of efficacy, cost and patient experience. Future financial projections and market analysis will need to account for these variables when assessing IceCure Medical's potential revenue growth.
- MRI reveals disappearance of hemorrhagic signal and development of necrotic changes
- Pain reduced from a median of 7 on a scale of 0 - 10 to a median of 1, with some patients reporting 0
Five doctors participated in the study, including interventional radiologist and ProSense® user Prof. Julien Frandon, who has previously led hands-on training sessions with ProSense® at multiple medical conferences.
The investigator-initiated single-site study enrolled 7 women, ages 30-45 years, with endometriosis in the abdominal wall and para-diaphragmatic areas. Treatment with ProSense® cryoablation took about 30 minutes.
One month following treatment, assessment by MRI revealed hemorrhagic signal had disappeared and necrotic changes developed. All patients were satisfied with the treatment and reported their pain decreased from a median of 7 on a visual analog scale of 0 –10 to a median of 1, with some patients reporting 0.
The study concluded that based on the investigator's experience, ProSense® and single-probe percutaneous cryoablation with liquid nitrogen appears to be a promising alternative that offers speed, minimally invasive qualities, safety and more cost-effective treatment of extra-pelvis endometriosis. Since the results are based on a limited number of patients, further data is required with a larger patient cohort to gain comprehensive understanding of this treatment approach.
Prof. Frandon commented, "At our hospital in Nimes, we use ProSense®️ because, as a single probe, liquid nitrogen-based system, it's easier for our team of interventional radiologists to use than traditional multi-probe, argon-based systems. Since 2019, we have performed more than 150 ProSense®️ procedures with great efficacy, safety and patient satisfaction. I'm happy to see a growing number of indications treated with cryoablation, benefitting patients from early, minimally-invasive intervention."
"While surgical removal would have been the standard of care treatment for endometriosis nodules, ProSense® gives interventional radiologists and other practitioners a safe and effective minimally-invasive option. We are very pleased that all patients treated in this study were relieved of their endometriosis condition and pain within as little as a month following treatment," stated IceCure CEO Eyal Shamir.
About ProSense®
The ProSense® Cryoablation System provides a minimally invasive treatment option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including breast, kidney, lung, and liver.
ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its easy, transportable design and liquid nitrogen utilization, ProSense® opens that door to fast and convenient office-based procedure for breast tumors.
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system is marketed and sold worldwide for the indications cleared and approved to date including in the
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statement in this press release when it discusses ProSense as being a promising alternative treatment for extra-pelvis endometriosis. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in
IR Contact:
Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914
Todd Kehrli
Phone: 310-625-4462
Logo - https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/icecures-prosense-a-promising-alternative-treatment-for-extra-pelvis-endometriosis-independent-study-presented-at-ecr-2024-302078348.html
SOURCE IceCure Medical
FAQ
What technology did IceCure Medical Ltd. develop for tumor destruction?
Where was the independent study on cryoablation technology conducted?
What were the key findings of the study presented at the European Congress of Radiology?
Who led the hands-on training sessions with ProSense® at multiple medical conferences?
How many women were enrolled in the investigator-initiated single-site study on endometriosis treatment?
